Ilumetri (Tildrakizumab)

Tildrakizumab is a selective humanized IgG1κ monoclonal antibody that binds to the p19 subunit of interleukin‑23. By blocking IL‑23 from interacting with its receptor, the drug suppresses downstream Th17‑driven inflammation, which is a key driver of the excessive skin cell growth seen in plaque psoriasis.

The prescribed dose of Ilumetri is determined by the treating physician based on the patient’s clinical condition and response. Typically, the medication is supplied as a 100 mg prefilled syringe for subcutaneous injection, and the prescriber decides the dosing interval and any subsequent adjustments.

The safety of Ilumetri during pregnancy and lactation has not been fully established, and it is classified as having an unknown pregnancy category. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To order Ilumetri, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After receiving the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain handling), and any necessary import documentation.

Ilumetri (tildrakizumab) belongs to the same IL‑23 inhibitor class as guselkumab and risankizumab. All three target the p19 subunit of IL‑23, but they differ in dosing frequency, molecular structure, and clinical trial outcomes. Ilumetri is typically administered every 12 weeks after the initial loading phase, offering a convenient schedule compared with some alternatives.

Ilumetri must be stored refrigerated at 2‑8 °C (36‑46 °F). The prefilled syringes should be kept in their original packaging, protected from light, and must not be frozen or shaken. If temporary storage at room temperature is unavoidable, the product may remain out of the refrigerator for no longer than 14 days, after which it should be discarded.

Ilumetri is given as a subcutaneous injection using a prefilled syringe. The injection is typically performed in the thigh, abdomen, or upper arm, rotating sites to reduce local irritation. Healthcare professionals should follow aseptic technique, and patients may be taught self‑administration after appropriate training.

The most serious risks include severe infections (such as tuberculosis or opportunistic fungal infections), hypersensitivity reactions including anaphylaxis, and the potential for malignancies like lymphoma or skin cancer. Patients should be monitored regularly for signs of infection, unexplained weight loss, or new skin lesions, and therapy should be discontinued if serious adverse events occur.

Ilumetri is contraindicated in individuals with known hypersensitivity to tildrakizumab or any of its excipients. It should also be avoided in patients with active, uncontrolled infections, and it is not recommended for use with live vaccines. Clinicians should assess each patient’s medical history before initiating therapy.